Omnicell buys Aesynt Holding

Share this content:

Omnicell Inc., which makes medication supply products, has bought Aesynt Holding Coöperatief U.A.

The combined company counts 4,000 acute-care facilities worldwide as its clients, and expects to record annual revenues of over $670 million. It will have approximately 2,200 employees. Omnicell moved into the post-acute market in 2013.

“The addition of Aesynt to the Omnicell family will add distinct capabilities in central pharmacy robotics, IV robotics, automated dispensing systems, and analytics. The strength of our combined offerings will deliver truly scalable innovation to support safe and efficient healthcare,” said Randall A. Lipps, founder, chairman, president and CEO Omnicell.

In connection with the acquisition, Omnicell has a $400 million senior secured credit facility with Wells Fargo Securities LLC as sole lead arranger and Wells Fargo Bank, National Association as administrative agent.